U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Israeli drugmaker Teva has appointed former Sandoz and Biogen executive Richard Francis to succeed current CEO Kare Schultz, who is scheduled to retire at the end of this year. Francis ...

Teva CEO Richard Francis said, "2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products.

Teva Pharmaceuticals' CEO advocates for quicker FDA generic drug approvals, which he argues would save the U.S. healthcare system money. Concurrently, the Trump administration has revised the number ...

Teva’s CEO Richard Francis, who’s been leading the company’s turnaround since his arrival in early 2023, helped provide some color on the guidance during a conference call with analysts.

More than a third (33%) of essential generic medicines were withdrawn from the Portuguese market in the last ten years, ...

The current health news highlights Abridge raising $250 million to boost AI medical documentation, layoffs involving ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full year 2024 financial results.